The stock of Caladrius Biosciences Inc (NASDAQ:CLBS) reached all time low today, Oct, 31 and still has $3.56 target or 12.00% below today’s $4.05 share price. This indicates more downside for the $24.13M company. This technical setup was reported by Barchart.com. If the $3.56 PT is reached, the company will be worth $2.90 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 15,809 shares traded hands. Caladrius Biosciences Inc (NASDAQ:CLBS) has declined 44.67% since March 29, 2016 and is downtrending. It has underperformed by 48.14% the S&P500.
Analysts await Caladrius Biosciences Inc (NASDAQ:CLBS) to report earnings on November, 3. They expect $-1.22 earnings per share, up 41.90% or $0.88 from last year’s $-2.1 per share. After $-1.33 actual earnings per share reported by Caladrius Biosciences Inc for the previous quarter, Wall Street now forecasts -8.27% EPS growth.
Caladrius Biosciences Inc (NASDAQ:CLBS) Ratings Coverage
Out of 4 analysts covering Caladrius Biosciences (NASDAQ:CLBS), 2 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 50% are positive. Caladrius Biosciences has been the topic of 7 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The stock of Caladrius Biosciences Inc (NASDAQ:CLBS) earned “Buy” rating by Maxim Group on Tuesday, December 22. On Friday, August 7 the stock rating was downgraded by Benchmark to “”. The firm has “Hold” rating given on Thursday, January 7 by Maxim Group. The stock of Caladrius Biosciences Inc (NASDAQ:CLBS) has “Buy” rating given on Tuesday, August 23 by Chardan Capital Markets. H.C. Wainwright upgraded Caladrius Biosciences Inc (NASDAQ:CLBS) on Friday, April 29 to “Buy” rating. The stock of Caladrius Biosciences Inc (NASDAQ:CLBS) has “Neutral” rating given on Friday, January 8 by H.C. Wainwright. The rating was maintained by Benchmark on Friday, January 8 with “Hold”.
According to Zacks Investment Research, “Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York.”
More notable recent Caladrius Biosciences Inc (NASDAQ:CLBS) news were published by: Globenewswire.com which released: “Caladrius Biosciences Begins Enrollment of Second Cohort of Phase 2 Trial of …” on October 31, 2016, also Marketwatch.com with their article: “Caladrius Biosciences Inc.” published on June 08, 2015, Globenewswire.com published: “Caladrius Biosciences, Inc. Enters Into Agreements To Raise $25 Million in …” on September 15, 2016. More interesting news about Caladrius Biosciences Inc (NASDAQ:CLBS) were released by: Quotes.Wsj.com and their article: “News Caladrius Biosciences Inc.CLBS” published on June 09, 2015 as well as Globenewswire.com‘s news article titled: “Caladrius Biosciences Receives FDA Fast Track Designation for CLBS03 to Treat …” with publication date: July 28, 2016.
CLBS Company Profile
Caladrius Biosciences, Inc., formerly NeoStem, Inc., incorporated on October 18, 1980, through its subsidiary, PCT, LLC, a Caladrius Company (PCT), provides development and manufacturing services to the cell therapy industry (which includes cell gene therapy). PCT specializes in cell and cell gene therapies. PCT offers development and manufacturing capabilities, quality systems, cell and tissue processing, logistics, storage and distribution and engineering solutions to clients with therapeutic candidates at all stages of development. The Company’s product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.